ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Juvenile idiopathic arthritis"

  • Abstract Number: 048 • 2023 Pediatric Rheumatology Symposium

    Comparative Efficacy and Safety of Ibuprofen and Naproxen in the Treatment of Oligoarticular Juvenile Idiopathic Arthritis (oJIA): Bi-national Cohort Study

    Orly Ohana1, Itay Marmor2, Liora Harel3, Shiri Rubin4, rotem tal5, Yoel Levinsky6, Orit Peled7 and Gil Amarilyo3, 1Pediatric C ward, Schneider Children's Medical Centre, Petach Tikva, Israel, 2Dana-Dwek Children's Hospital, Hod Hasharon, Israel, 3Pediatric rheumatology clinic, Schneider children's medical center of Israel, Petach Tikva, Israel, 4Pediatric Ear Nose and Throat Unit Unit, Schneider Children's Medical Center of Israel, Petach Tikva, Israel, 5Schneider Children's Medical Center of Israel, Petach Tikva, Israel, 6Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, 7Department of Pharmacy, Schneider Children's Medical Center of Israel, Petach Tikva, Israel

    Background/Purpose: JIA is the most common childhood rheumatic disease. NSAIDs and intraarticular corticosteroid injections (IACI) are first-line therapy for oJIA. NSAIDs Adverse events (AEs) include…
  • Abstract Number: 125 • 2023 Pediatric Rheumatology Symposium

    Measurable Outcomes of an Ophthalmology and Rheumatology Coordinated Care Clinic

    Catherine Lavallee1, Sabrina Gmuca2 and Melissa Lerman2, 1Virginia Tech Carilion School of Medicine, ROANOKE, VA, 2Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose: Non-infectious pediatric uveitis is a vision threatening disease whose treatment involves both ophthalmologists and rheumatologists.In other diseases necessitating multidisciplinary care, coordinated care clinics have…
  • Abstract Number: 059 • 2023 Pediatric Rheumatology Symposium

    Update of Clinical and Laboratory Features of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease (SJIA-LD) Cohort

    Esraa Eloseily1, Min-Lee Chang2, Mary Ellen Riordan3, allan Russell4, Marc Natter2, Yukiko Kimura5 and Grant Schulert1, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Boston Children's Hospital, Boston, MA, 3Hackensack Meridian Health/ Joseph M. Sanzari Children's Hospital, Hackensack, NJ, 4Duke Clinical Research Institute, Durham, NC, 5Hackensack Meridian School of Medicine, Hackensack, NJ

    Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) associated lung disease (SJIA-LD) is an emerging and life-threatening clinical problem. Despite recent advances, there remain key unanswered questions…
  • Abstract Number: 126 • 2023 Pediatric Rheumatology Symposium

    Facilitating Peer-to-Peer Conversations Around Key Clinical Trial Recruitment Barriers in the Limit-JIA Trial Using Low-Fidelity Video Capture

    Melanie Kohlheim1, Eveline Wu2, Laura Schanberg3, Vincent Del Gaizo1, Catherine Lavallee4, Marc Natter5, Katie Clem6, Brian Shakley6 and Kevin Urban7, 1CARRA, Washington, DC, 2UNC Chapel Hill, Chapel Hill, NC, 3Duke University Medical Center, Durham, NC, 4Virginia Tech Carilion School of Medicine, ROANOKE, VA, 5Boston Children's Hospital, Boston, MA, 6LIFT 1428, Llc, Ooltewah, TN, 7Business Coaching for Creatives, New York, NY

    Background/Purpose: The LIMIT-JIA trial aims to study if early abatacept treatment can prevent disease extension in children with recent-onset, uncomplicated, and oligoarticular or limited JIA.…
  • Abstract Number: L12 • ACR Convergence 2022

    First Line Treatment Using Recombinant IL-1Receptor Antagonist in New Onset Systemic Juvenile Idiopathic Arthritis Is an Effective Treatment Strategy, Irrespective of HLA DRB1 Background

    Remco Erkens1, Rashmi Sinha2, Alex Pickering3, Grant Schulert4, Alexei Grom4, Lars van der Veken1, Hanneke van Deutekom1, Jorg Calis1, Jorg van Loosdregt5 and Sebastiaan Vastert1, 1University Medical Center Utrecht, Utrecht, Netherlands, 2Systemic JIA Foundation, Cincinnati, OH, 3Systemic JIA Foundation, San Francisso, CA, 4Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5University Medical Center Utrecht, Wilhelmina Children's Hospital, Zeist, Netherlands

    Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) is a severe subtype of JIA. Recently, interstitial lung disease (SJIA-LD) has been reported as a severe complication of…
  • Abstract Number: 0853 • ACR Convergence 2022

    Reliability of MRI Lesions Comprising the Preliminary OMERACT Juvenile Idiopathic Arthritis MRI Score (OMERACT JAMRI-SIJ): What Is the Impact of Systematic Reader Calibration?

    Walter P Maksymowych1, Nisha Varma2, Arthur Meyers3, Jennifer Stimec4, Nikolay Tzaribachev5, Jonathan Akikusa6, Tarimobo Otobo4, Marion von Rossum7, Andrea Doria4 and Nele Herregods8, 1Department of Medicine, University of Alberta, Edmonton, AB, Canada, 2Department of Paediatric Radiology, The Royal Children's Hospital Melbourne, Melbourne, Australia, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Department of Diagnostic Imaging, SickKids, University of Toronto, Toronto, ON, Canada, 5PRI Research Institute, Bad Bramstedt, Germany, 6Rheumatology Service, Royal Children’s Hospital, Melbourne, Melbourne, Australia, 7Emma Children’s Hospital, Dept Pediatrics, Amsterdam University Medical Centers, Amsterdam, Netherlands, 8Ghent University Hospital, Ghent, Belgium

    Background/Purpose: The evaluation of the sacroiliac joints (SIJ) in children with Juvenile Idiopathic Arthritis (JIA) increasingly relies on the use of MRI since radiography is…
  • Abstract Number: 0875 • ACR Convergence 2022

    Predictive Biomarkers of Tofacitinib Response and Disease Activity in Juvenile Idiopathic Arthritis Subtypes: A Longitudinal Study

    Ekemini Ogbu1, Sherry Thornton2, Alyssa Sproles2, Alexei Grom3, Sanjeev Dhakal4, Bin Huang5 and Hermine Brunner6, 1Cincinnati Children's Hospital Medical Center, Atlanta, GA, 2Cincinnati Children's Hospital, Cincinnati, OH, 3Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 4Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Cincinnati Children's Hospital Medical Center, Cinciannati, OH, 6Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH

    Background/Purpose: Tofacitinib has been shown to improve disease activity of several subtypes of Juvenile Idiopathic Arthritis (JIA). No known biomarkers to date predict JIA improvement…
  • Abstract Number: 2210 • ACR Convergence 2022

    Baricitinib in Juvenile Idiopathic Arthritis: A Phase 3, Double-Blind, Placebo-Controlled, Withdrawal, Efficacy and Safety Study

    Athimalaipet Ramanan1, Pierre Quartier Dit Maire2, Nami Okamoto3, Gabriella Meszaros4, Joana Araujo4, Zhongkai Wang4, Ran Liao4, Brenda Crowe4, Xin Zhang4, Rodney Decker4, Stuart Keller4, Hermine Brunner5 and Nicola Ruperto6, 1Bristol Royal Hospital for Children, Bristol, United Kingdom, 2Necker hospital, Paris Cedex 15, France, 3Osaka Medical College, Takatsuki-city, Japan, 4Eli Lilly and Company, Indianapolis, IN, 5Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH, 6IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy

    Background/Purpose: Baricitinib is a JAK1/2 selective inhibitor approved for the treatment of rheumatoid arthritis. Juvenile idiopathic arthritis (JIA) is a group of diseases characterized by…
  • Abstract Number: 0854 • ACR Convergence 2022

    Outcome of Uveitis in Juvenile Idiopathic Arthritis and Spondyloarthritis Patients – a 5-year Follow up Study

    Filipe Pinheiro1, Mariana Leuzinger-Dias2, Bruno Fernandes3, Diogo Fonseca4, Joana Vilaça5, Luís Figueira6 and Iva Brito7, 1Rheumatology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, 2Ophtalmology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, 3Rheumatology Deparment, Centro Hospitalar e Universitário de São João, Porto, Portugal, 4Rheumatology Department, Centro Hospitalar de Vila Nova de Gaia / Espinho, Vila Nova de Gaia, Portugal, 5Paediatrics Department, Hospital de Braga, Braga, Portugal, 6Ophthalmology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, 7Pediatric and Young Adult Rheumatology Unit, Centro Hospitalar Universitário de São João, Porto, Portugal

    Background/Purpose: Uveitis is a frequent complication of juvenile idiopathic arthritis (JIA) and juvenile spondyloarthritis (jSpA), and diagnosis is often challenging. The importance of uveitis relates…
  • Abstract Number: 0876 • ACR Convergence 2022

    Investigation of Predictive Factors for Active Disease Status Within 24 Months of Juvenile Idiopathic Arthritis Diagnosis

    Erin Balay1 and Susan Shenoi2, 1University of Washington, Seattle Children's Hospital, Seattle, WA, 2Seattle Children's Hospital and Research Center / University of Washington, Seattle, WA

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common rheumatologic disease in children. JIA disease course and prognosis varies significantly between its seven categories, and…
  • Abstract Number: 2211 • ACR Convergence 2022

    Identification of Plasma Metabolomic Biomarkers of Juvenile Idiopathic Arthritis

    Amar Kumar1, Joshua Tartarian2, Valentina Shakhnovich3, Carl Langefeld4, Daniel Lovell5, Susan Thompson6, Mara Becker7 and Ryan Funk8, 1University of Kansas, Kansas City, KS, 2University of Kansas Medical Center, Kansas City, KS, 3University of Missouri-Kansas City School of Medicine & Children’s Mercy Kansas City, Kansas City, MO, 4Wake Forest School of Medicine, Winston Salem, NC, 5Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 6Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Blue Ash, OH, 7Duke University Medical Center/Duke Clinical Research Institute, Durham, NC, 8University of Kansas, Leawood, KS

    Background/Purpose: Identification of disease and therapeutic biomarkers remains a barrier to the early diagnosis of and initiation of effective therapy for juvenile idiopathic arthritis (JIA).…
  • Abstract Number: 0855 • ACR Convergence 2022

    Change in Short Term Outcomes Following Tolerated Disease Activity Level for Individuals with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry

    Melissa Mannion1, Fenglong Xie1, Timothy Beukelman1, Jeffrey Curtis2 and , for the CARRA Registry Investigators3, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Hoover, AL, 3CARRA, Washington, DC

    Background/Purpose: Current recommendations suggest treatment escalation for juvenile idiopathic arthritis (JIA) until the disease activity target is reached, ideally inactive or low disease activity. Our…
  • Abstract Number: 0877 • ACR Convergence 2022

    Neutrophils Extracellular Traps Formation May Serve as a Biomarker for Disease Activity in Oligoarticular Juvenile Idiopathic Arthritis

    Merav Heshin-Bekenstein1, Szilvia Baron2, Grant Schulert3, Anna Shusterman4, Rachel Shukrun4, Yoav Binenbaum4 and Ronit Elhasid5, 1Dana Dwek Children's Hospital, Tel Aviv Medical Center Israel, Binyamina, Israel, 2Pediatric Hemato-Oncology Research Laboratory, Tel Aviv Medical Center, Tel Aviv, Israel, 3Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Tel Aviv Medical Center, Tel Aviv, Israel, 5Dana Children's Hospital, Tel Aviv Medical Center, Tel Aviv, Israel

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children, causing significant morbidity. Despite the dramatic improvement in treatment, many patients…
  • Abstract Number: 2213 • ACR Convergence 2022

    Multi-omic Analysis of Macrophage Activation Syndrome Associated with sJIA Reveals a Potential Role of Type I Interferons in the Expansion of Cycling T Cells

    Kailey Brodeur1, Liang Chen1, zhengping huang2, Yan Du1, Holly Wobma3, Maria Taylor4, Joyce Chang3, Megan Day-Lewis3, Fatma Dedeoglu3, Olha Halyabar3, Mindy Lo3, Jane W. Newburger5, Mary Beth F. Son3, Robert Sundel3, Peter Nigrovic3, lauren henderson3 and Pui Lee3, 1Boston Children's Hospital, Boston, MA, 2Guangdong Second Provincial Hospital, Guangzhou, China, 3Division of Immunology, Boston Children's Hospital, Boston, MA, 4Division of Immunology, Boston Children's Hospital, Brighton, MA, 5Department of Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Macrophage activation syndrome (MAS) is a complication of systemic juvenile idiopathic arthritis (sJIA) characterized by cytokine storm and overt immune cell activation. We aim…
  • Abstract Number: 0856 • ACR Convergence 2022

    A Cross-Sectional Description of Physical Activity (PA) in Children with Juvenile Idiopathic Arthritis (JIA): The LEAP Study (Linking Exercise, Activity, and Pathophysiology in Canadian Children with Arthritis)

    Lori Tucker1, Jaime Guzman2, Lamia Hayawi3, Nick Barrowman3, Heather Macdonald4, Kristin Houghton5, David Cabral6, Bianca Lang7, Dax Rumsey8, Elizabeth Stringer9, Shirley Tse10, Roberta Berard11, Claire Leblanc12, Tommy Gerschman13, Liane Heale14, Karen Watanabe-Duffy15, Sarah Campillo12, Natalie Shiff16 and Ciaran Duffy17, 1British Columbia Children's Hospital, Vancouver, BC, Canada, 2University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada, 3Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada, 4University of British Columbia, Vancouver, BC, Canada, 5University of British Columbia - Vancouver, Vancouver, BC, Canada, 6BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, 7Dalhousie University - Halifax, Halifax, NS, Canada, 8Stollery Children's Hospital, Edmonton, AB, Canada, 9IWK Hospital, Halifax, NS, Canada, 10Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 11London Health Sciences Centre, London, ON, Canada, 12McGill University, Montréal, QC, Canada, 13University of British Columbia - Vancouver, North Vancouver, BC, Canada, 14McMaster University, Oakville, ON, Canada, 15Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, 16Janssen Scientific Affairs, LLC, Horsham, PA, USA/ Department of Community Health and Epidemiology, College of Medicine, University of Saskatchewan, Saskatoon, Canada, Philadelphia, PA, 17University of Ottawa, Ottawa, ON, Canada

    Background/Purpose: Participation in physical activity (PA) is a concern of children with JIA , however, factors associated with PA in these children are incompletely understood. …
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 20
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology